NEA Management Company LLC held its position in Cerecor Inc. (NASDAQ:CERC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 595,435 shares of the company’s stock at the end of the second quarter. NEA Management Company LLC owned about 4.23% of Cerecor worth $341,000 at the end of the most recent quarter.
Cerecor Inc. (CERC) opened at 0.62 on Friday. Cerecor Inc. has a 12-month low of $0.34 and a 12-month high of $5.60. The company’s 50-day moving average is $0.72 and its 200 day moving average is $0.67. The stock’s market capitalization is $8.22 million.
Cerecor (NASDAQ:CERC) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.15. The company had revenue of $0.16 million during the quarter. Cerecor had a negative net margin of 1,106.99% and a negative return on equity of 1,325.84%. On average, equities research analysts expect that Cerecor Inc. will post ($1.07) earnings per share for the current fiscal year.
In other news, major shareholder Armistice Capital Master Fund acquired 954,228 shares of Cerecor stock in a transaction on Wednesday, August 16th. The stock was acquired at an average cost of $0.61 per share, for a total transaction of $582,079.08. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 10.70% of the stock is currently owned by company insiders.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
What are top analysts saying about Cerecor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerecor Inc. and related companies.